Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05219162 | Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).(GPS) | completed | Phase 4 | 182 | AstraZenecaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03712969 | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | completed | Phase 4 | 527 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03655834 | Dose Individualization of Pemetrexed - IMPROVE-III(IMPROVE-III) | completed | Phase 4 | 10 | Radboud University Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03853551 | Osimertinib Study in Indian Patients | completed | Phase 4 | 60 | AstraZenecaINDUSTRY | 1 | Jun 3, 2021 | clinicaltrials |
| NCT03607149 | Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies(PKAPIR) | completed | Phase 4 | 11 | Centre Georges Francois LeclercOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT03444766 | Study of Nivolumab for Advanced Cancers in India | completed | Phase 4 | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT02514174 | Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older | completed | Phase 4 | 25 | Boehringer IngelheimINDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT03550482 | Oncoxin® and Quality of Life in Cancer Patients | completed | Phase 4 | 133 | Catalysis SLINDUSTRY | 2 | Jun 5, 2019 | clinicaltrials |
| NCT03092986 | Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer | completed | Phase 4 | 60 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02208843 | Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | completed | Phase 4 | 60 | Boehringer IngelheimINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT02151149 | Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly(ABOUND 70+) | completed | Phase 4 | 143 | CelgeneINDUSTRY | 1 | Sep 24, 2018 | clinicaltrials |
| NCT03384511 | The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | completed | Phase 4 | 38 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT02316327 | Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab | completed | Phase 4 | 19 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT01066884 | A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 4 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT00770588 | Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)(INFORM) | completed | Phase 4 | 296 | AstraZenecaINDUSTRY | 1 | Feb 8, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01609543 | A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations | completed | Phase 4 | 62 | Hoffmann-La RocheINDUSTRY | 3 | Feb 1, 2016 | clinicaltrials |
| NCT02000531 | Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population | completed | Phase 4 | 45 | Hoffmann-La RocheINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01196078 | A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT02497118 | Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC | completed | Phase 4 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 14, 2015 | clinicaltrials |
| NCT01287754 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations | completed | Phase 4 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Jun 2, 2015 | clinicaltrials |
| NCT01230710 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression | completed | Phase 4 | 51 | Hoffmann-La RocheINDUSTRY | 1 | Mar 30, 2015 | clinicaltrials |
| NCT01465243 | Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose | completed | Phase 4 | 32 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 17, 2014 | clinicaltrials |
| NCT00883675 | Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer | completed | Phase 4 | 133 | Michael MannNETWORK | 2 | Dec 18, 2013 | clinicaltrials |
| NCT00762346 | Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis | completed | Phase 4 | 156 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT00765687 | Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates(BLEST) | completed | Phase 4 | 432 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT01020786 | A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients | completed | Phase 4 | 109 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 27, 2013 | clinicaltrials |
| NCT00829322 | Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 | completed | Phase 4 | 208 | University of OxfordOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00608868 | SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients(SELINE) | completed | Phase 4 | 156 | AstraZenecaINDUSTRY | 1 | Sep 28, 2012 | clinicaltrials |
| NCT01442909 | Pemetrexed Followed by Docetaxel or in Reverse Sequence | completed | Phase 4 | 44 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Sep 29, 2011 | clinicaltrials |
| NCT00686322 | Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) | completed | Phase 4 | 6 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Sep 15, 2011 | clinicaltrials |
| NCT00380718 | Chemotherapy for Patients With Non-Small Cell Lung Cancer | completed | Phase 4 | 33 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 16, 2010 | clinicaltrials |
| NCT01000740 | A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa | completed | Phase 4 | 59 | AstraZenecaINDUSTRY | 1 | May 21, 2010 | clinicaltrials |
| NCT00099541 | Non-small Cell Lung Cancer Registry | completed | Phase 4 | 300 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00115206 | Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy | completed | Phase 4 | — | AmgenINDUSTRY | 0 | Apr 6, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Apr 7, 2026source: clinicaltrials